Please login to the form below

Not currently logged in
Email:
Password:

Pfizer may counter Daiichi's bid for Ranbaxy

Pfizer may be about to bid for a 65 per cent share of Indian generics company, Ranbaxy, according to a Business Standard report
Pfizer may be about to bid for a 65 per cent share of Indian generics company, Ranbaxy, according to a report in the Business Standard newspaper.

Ranbaxy, founded by the Singh family, has agreed a deal with Japan's Daiichi Sankyo, worth up to $4.6bn to take control of the company. However, it is rumoured that Pfizer, which held talks with Ranbaxy a year ago, may be about to make a counter bid.

According to the newspaper, a Ranbaxy spokesman said: "We have a binding contract with Daiichi. It is a final contract."

Pfizer has lost out to Ranbaxy in several international battles over the patent rights to Lipitor, its cholesterol drug. In most countries the patent will start expiring in 2011.

13th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics